166 related articles for article (PubMed ID: 34955538)
1. Testosterone Recovery after Neoadjuvant Gonadotropin-Releasing Hormone Antagonist versus Agonist on Permanent Iodine-125 Seed Brachytherapy in Prostate Cancer Patients: A Propensity Score Analysis.
Iwata T; Maruyama Y; Kawada T; Sadahira T; Katayama S; Takamoto A; Sako T; Wada K; Edamura K; Kobayashi Y; Araki M; Watanabe M; Watanabe T; Nasu Y
Acta Med Okayama; 2021 Dec; 75(6):705-711. PubMed ID: 34955538
[TBL] [Abstract][Full Text] [Related]
2. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
4. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
5. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
6. Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy.
Kato Y; Shigehara K; Kawaguchi S; Izumi K; Kadono Y; Mizokami A
Aging Male; 2020 Dec; 23(5):1210-1216. PubMed ID: 32096413
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.
Ezaki T; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Oya M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):301-6. PubMed ID: 26055219
[TBL] [Abstract][Full Text] [Related]
9. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
10. Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study.
Mytilekas VK; Papaefstathiou E; Koukourikis P; Ouzounidis X; Kazantzidis S; Hatzimouratidis K
Investig Clin Urol; 2023 Nov; 64(6):572-578. PubMed ID: 37932568
[TBL] [Abstract][Full Text] [Related]
11. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.
Masson-Lecomte A; Guy L; Pedron P; Bruyere F; Rouprêt M; Nsabimbona B; Dahan M; Hoffman P; Salomon L; Vordos D; Hoznek A; Le Corvoisier P; Morel P; Abbou C; de la Taille A
World J Urol; 2013 Apr; 31(2):339-43. PubMed ID: 22527669
[TBL] [Abstract][Full Text] [Related]
12. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
13. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
[TBL] [Abstract][Full Text] [Related]
16. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
17. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
Gaudet M; Vigneault É; Foster W; Meyer F; Martin AG
Radiother Oncol; 2016 Jan; 118(1):141-7. PubMed ID: 26702991
[TBL] [Abstract][Full Text] [Related]
18. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
19. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
20. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
